Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Company Overview - Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines through base editing [3] - The company aims to establish a leading, fully integrated platform for precision genetic medicines, incorporating a suite of gene editing and delivery technologies [3] - Beam is building internal manufacturing capabilities to support its gene editing technologies, particularly its proprietary base editing technology [3] Upcoming Events - John Evans, the CEO of Beam Therapeutics, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025, at 2:30 p.m. ET in New York [1] - A live webcast of the event will be available on the company's investor section of the website and will be archived for 60 days [2]